Cargando…

Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic

PURPOSE: Performance status (PS) is a key factor in oncologic decision making, but conventional scales used to measure PS vary among observers. Consumer-grade biometric sensors have previously been identified as objective alternatives to the assessment of PS. Here, we investigate how one such biomet...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasnain, Zaki, Nilanon, Tanachat, Li, Ming, Mejia, Aaron, Kolatkar, Anand, Nocera, Luciano, Shahabi, Cyrus, Cozzens Philips, Frankie A., Lee, Jerry S.H., Hanlon, Sean E., Vaidya, Poorva, Ueno, Naoto T., Yennu, Sriram, Newton, Paul K., Kuhn, Peter, Nieva, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328110/
https://www.ncbi.nlm.nih.gov/pubmed/32598179
http://dx.doi.org/10.1200/CCI.20.00010
_version_ 1783552681174892544
author Hasnain, Zaki
Nilanon, Tanachat
Li, Ming
Mejia, Aaron
Kolatkar, Anand
Nocera, Luciano
Shahabi, Cyrus
Cozzens Philips, Frankie A.
Lee, Jerry S.H.
Hanlon, Sean E.
Vaidya, Poorva
Ueno, Naoto T.
Yennu, Sriram
Newton, Paul K.
Kuhn, Peter
Nieva, Jorge
author_facet Hasnain, Zaki
Nilanon, Tanachat
Li, Ming
Mejia, Aaron
Kolatkar, Anand
Nocera, Luciano
Shahabi, Cyrus
Cozzens Philips, Frankie A.
Lee, Jerry S.H.
Hanlon, Sean E.
Vaidya, Poorva
Ueno, Naoto T.
Yennu, Sriram
Newton, Paul K.
Kuhn, Peter
Nieva, Jorge
author_sort Hasnain, Zaki
collection PubMed
description PURPOSE: Performance status (PS) is a key factor in oncologic decision making, but conventional scales used to measure PS vary among observers. Consumer-grade biometric sensors have previously been identified as objective alternatives to the assessment of PS. Here, we investigate how one such biometric sensor can be used during a clinic visit to identify patients who are at risk for complications, particularly unexpected hospitalizations that may delay treatment or result in low physical activity. We aim to provide a novel and objective means of predicting tolerability to chemotherapy. METHODS: Thirty-eight patients across three centers in the United States who were diagnosed with a solid tumor with plans for treatment with two cycles of highly emetogenic chemotherapy were included in this single-arm, observational prospective study. A noninvasive motion-capture system quantified patient movement from chair to table and during the get-up-and-walk test. Activity levels were recorded using a wearable sensor over a 2-month period. Changes in kinematics from two motion-capture data points pre- and post-treatment were tested for correlation with unexpected hospitalizations and physical activity levels as measured by a wearable activity sensor. RESULTS: Among 38 patients (mean age, 48.3 years; 53% female), kinematic features from chair to table were the best predictors for unexpected health care encounters (area under the curve, 0.775 ± 0.029) and physical activity (area under the curve, 0.830 ± 0.080). Chair-to-table acceleration of the nonpivoting knee (t = 3.39; P = .002) was most correlated with unexpected health care encounters. Get-up-and-walk kinematics were most correlated with physical activity, particularly the right knee acceleration (t = −2.95; P = .006) and left arm angular velocity (t = −2.4; P = .025). CONCLUSION: Chair-to-table kinematics are good predictors of unexpected hospitalizations, whereas the get-up-and-walk kinematics are good predictors of low physical activity.
format Online
Article
Text
id pubmed-7328110
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-73281102021-06-29 Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic Hasnain, Zaki Nilanon, Tanachat Li, Ming Mejia, Aaron Kolatkar, Anand Nocera, Luciano Shahabi, Cyrus Cozzens Philips, Frankie A. Lee, Jerry S.H. Hanlon, Sean E. Vaidya, Poorva Ueno, Naoto T. Yennu, Sriram Newton, Paul K. Kuhn, Peter Nieva, Jorge JCO Clin Cancer Inform Original Reports PURPOSE: Performance status (PS) is a key factor in oncologic decision making, but conventional scales used to measure PS vary among observers. Consumer-grade biometric sensors have previously been identified as objective alternatives to the assessment of PS. Here, we investigate how one such biometric sensor can be used during a clinic visit to identify patients who are at risk for complications, particularly unexpected hospitalizations that may delay treatment or result in low physical activity. We aim to provide a novel and objective means of predicting tolerability to chemotherapy. METHODS: Thirty-eight patients across three centers in the United States who were diagnosed with a solid tumor with plans for treatment with two cycles of highly emetogenic chemotherapy were included in this single-arm, observational prospective study. A noninvasive motion-capture system quantified patient movement from chair to table and during the get-up-and-walk test. Activity levels were recorded using a wearable sensor over a 2-month period. Changes in kinematics from two motion-capture data points pre- and post-treatment were tested for correlation with unexpected hospitalizations and physical activity levels as measured by a wearable activity sensor. RESULTS: Among 38 patients (mean age, 48.3 years; 53% female), kinematic features from chair to table were the best predictors for unexpected health care encounters (area under the curve, 0.775 ± 0.029) and physical activity (area under the curve, 0.830 ± 0.080). Chair-to-table acceleration of the nonpivoting knee (t = 3.39; P = .002) was most correlated with unexpected health care encounters. Get-up-and-walk kinematics were most correlated with physical activity, particularly the right knee acceleration (t = −2.95; P = .006) and left arm angular velocity (t = −2.4; P = .025). CONCLUSION: Chair-to-table kinematics are good predictors of unexpected hospitalizations, whereas the get-up-and-walk kinematics are good predictors of low physical activity. American Society of Clinical Oncology 2020-06-29 /pmc/articles/PMC7328110/ /pubmed/32598179 http://dx.doi.org/10.1200/CCI.20.00010 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Reports
Hasnain, Zaki
Nilanon, Tanachat
Li, Ming
Mejia, Aaron
Kolatkar, Anand
Nocera, Luciano
Shahabi, Cyrus
Cozzens Philips, Frankie A.
Lee, Jerry S.H.
Hanlon, Sean E.
Vaidya, Poorva
Ueno, Naoto T.
Yennu, Sriram
Newton, Paul K.
Kuhn, Peter
Nieva, Jorge
Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
title Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
title_full Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
title_fullStr Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
title_full_unstemmed Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
title_short Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
title_sort quantified kinematics to evaluate patient chemotherapy risks in clinic
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328110/
https://www.ncbi.nlm.nih.gov/pubmed/32598179
http://dx.doi.org/10.1200/CCI.20.00010
work_keys_str_mv AT hasnainzaki quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT nilanontanachat quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT liming quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT mejiaaaron quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT kolatkaranand quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT noceraluciano quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT shahabicyrus quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT cozzensphilipsfrankiea quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT leejerrysh quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT hanlonseane quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT vaidyapoorva quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT uenonaotot quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT yennusriram quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT newtonpaulk quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT kuhnpeter quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic
AT nievajorge quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic